Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Subcutaneous Immunoglobulin (SCIG) Market’s Growth Trajectory From 2025 To 2034?
The market for subcutaneous immunoglobulin (SCIG) has seen a swift expansion in the recent past. It is predicted to surge from $12.72 billion in 2024 to $14.39 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.1%. The notable growth in the past can be credited to factors like an upsurge in the occurrence of immunodeficiency disorders, an inclination towards home-based care among patients, improved therapeutic efficacy, an increase in recognition and diagnostic rates, as well as enhancement in favorable reimbursement policies.
Rapid expansion is foreseen for the subcutaneous immunoglobulin (SCIG) market in the approaching years, with predictions showing it swelling to $23.23 billion in 2029, showcasing a compound annual growth rate (CAGR) of 12.7%. This surge throughout the forecast period can be credited to the escalating occurrences of neurological disorders and autoimmune diseases, heightened awareness and acceptance of immunoglobulin therapy, expanded uses in neurology and dermatology, and the growth of healthcare facilities. The forecast period will also be marked by key tendencies including breakthroughs in drug delivery systems, an increased request for home infusion therapies, advancements in antibody therapy, formulation innovations, and fresh developments in SCIG.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
Which Primay Drivers Are Accelerating Growth in the Subcutaneous Immunoglobulin (SCIG) Market?
The escalating incidence of secondary immunodeficiency diseases is predicted to fuel the expansion of the subcutaneous immunoglobulin market in the future. Secondary immunodeficiency diseases are disorders where the immune system is weakened or compromised due to factors other than the immune system itself. The increase in these diseases is influenced by various elements such as aging populations, immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies which aid in enhancing the weakened immune system, particularly in chronic disorders like HIV or autoimmune diseases. This therapy helps prevent infections and maintains immunological function during treatment. For example, in October 2023, the UK Health Security Agency, a government agency based in the UK, reported an increase of 22% from the previous year, with 3,805 new HIV diagnoses in England in 2022. As such, the rising incidence of secondary immunodeficiency diseases is fueling the expansion of the subcutaneous immunoglobulin market.
Which Primary Segments of the Subcutaneous Immunoglobulin (SCIG) Market Are Driving Growth and Industry Transformations?
The subcutaneous immunoglobulin (scig) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Subcutaneous Immunoglobulin (SCIG) Market?# Market?
North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Technological Trends Are Reshaping the Subcutaneous Immunoglobulin (SCIG) Industry Dynamics?
In the subcutaneous immunoglobulin market, primary corporations are innovating with the creation of subcutaneous human-klhw, a unique blend that includes human immune globulins (Ig), enhancing the body’s immunity. This product, intended for subcutaneous use, is instrumental in treating primary immunodeficiency diseases. For example, Grifols S.A., a pharmaceutical corporation based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This innovation is designed specifically to address primary immunodeficiency and cater to individuals with compromised immune systems. XEMBIFY is a ready-made formula that simplifies treatment procedures and enhances patient comfort. Its stability at room temperature for up to two years eliminates the need for cool storage during transit, making it advantageous across various healthcare environments.
View the full report here:
What Parameters Are Used to Define the Subcutaneous Immunoglobulin (SCIG) Market?
Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model